Akero Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2017-01-01
- Employees
- 56
- Market Cap
- $1.8B
- Website
- http://www.akerotx.com
- Introduction
Akero Therapeutics, Inc. is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company was founded by Jonathan Young and Timothy Rolph in January 2017 and is headquartered in South San Francisco, CA.
A Study Evaluating Efruxifermin in Subjects with Compensated Cirrhosis Due to NASH/MASH
- Conditions
- NASH - Nonalcoholic SteatohepatitisMASH - Metabolic Dysfunction-Associated Steatohepatitis
- Interventions
- Drug: EfruxiferminDrug: Placebo
- First Posted Date
- 2024-07-30
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Akero Therapeutics, Inc
- Target Recruit Count
- 1150
- Registration Number
- NCT06528314
- Locations
- 🇪🇸
Akero Clinical Study Site, Santander, Cantabria, Spain
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
- Conditions
- NASH With FibrosisMASH With Fibrosis
- Interventions
- Drug: EfruxiferminDrug: Placebo
- First Posted Date
- 2024-01-22
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Akero Therapeutics, Inc
- Target Recruit Count
- 1650
- Registration Number
- NCT06215716
- Locations
- 🇬🇧
Akero Clinical Study Site, Newcastle-upon-Tyne, England, United Kingdom
A Study Evaluating Efruxifermin in Subjects with Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
- Conditions
- NAFLD/MASLDNASH/MASH
- Interventions
- Drug: EfruxiferminDrug: Placebo
- First Posted Date
- 2023-12-08
- Last Posted Date
- 2024-11-07
- Lead Sponsor
- Akero Therapeutics, Inc
- Target Recruit Count
- 700
- Registration Number
- NCT06161571
- Locations
- 🇬🇧
Akero Clinical Study Site, Newcastle-upon-Tyne, England, United Kingdom
A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (Symmetry)
- Conditions
- NASH - Nonalcoholic Steatohepatitis
- Interventions
- Drug: EFXDrug: Placebo
- First Posted Date
- 2021-09-09
- Last Posted Date
- 2023-04-25
- Lead Sponsor
- Akero Therapeutics, Inc
- Target Recruit Count
- 200
- Registration Number
- NCT05039450
- Locations
- 🇵🇷
Akero Clinical Study Site, San Juan, Puerto Rico
A Study of Efruxifermin in Non-Cirrhotic Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)
- Conditions
- NASH - Nonalcoholic Steatohepatitis
- Interventions
- Drug: EFXDrug: Placebo
- First Posted Date
- 2021-02-23
- Last Posted Date
- 2023-04-21
- Lead Sponsor
- Akero Therapeutics, Inc
- Target Recruit Count
- 128
- Registration Number
- NCT04767529
- Locations
- 🇵🇷
Akero Clinical Study Site, San Juan, Puerto Rico
A Study of Efruxifermin in Subjects With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)
- Conditions
- NASH - Nonalcoholic Steatohepatitis
- Interventions
- Drug: PlaceboDrug: EFX
- First Posted Date
- 2019-06-06
- Last Posted Date
- 2022-08-04
- Lead Sponsor
- Akero Therapeutics, Inc
- Target Recruit Count
- 110
- Registration Number
- NCT03976401
- Locations
- 🇵🇷
Akero Clinical Study Site, San Juan, Puerto Rico